Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Corral-Jaime, J. (Jesús)|||/items/aba4503e-6970-43e0-9219-238766ac8852; Mok, T.S. (Tony S.)|||/items/e91edeb3-d511-44a4-a72c-338e96ade778; Nakagawa, K. (Kazuhiko)|||/items/04e7db33-fd42-4c2b-a989-0d6a89ae878a; Rosell, R. (Rafael)|||/items/771e36b5-84e0-4ac6-9009-324f454c04b0; Lee, K.H. (Ki Hyeong)|||/items/494d4428-b76a-475d-a658-c74ee1ade123; Migliorino, M.R. (Maria Rita)|||/items/9abafe36-e406-4036-b7f4-de06f44c197f; Pluzanski, A. (Adam)|||/items/60793365-1e98-4ea9-8e43-b3df9623206c; Linke, R. (Rolf)|||/items/07873284-7c5d-4745-b966-cff39ed3b29d; Devgan, G. (Geeta)|||/items/fb3e0082-1314-470f-91f3-6e2b9787a62d; Tan, W. (Weiwei)|||/items/55ef5622-8ca9-4887-a576-36b6711f47dc; Quinn, S. (Susan)|||/items/1e0851a9-c13a-4765-97f3-d086cb24a7cc; Wang, T. (Tao)|||/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3; Wu, Y.L. (Yi-Long)|||/items/7a103463-4dcc-4ad4-87d3-0c0081a787df

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed p...

Descripción completa

Detalles Bibliográficos
Autores:	Corral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852, Mok, T.S. (Tony S.)\|\|\|/items/e91edeb3-d511-44a4-a72c-338e96ade778, Nakagawa, K. (Kazuhiko)\|\|\|/items/04e7db33-fd42-4c2b-a989-0d6a89ae878a, Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0, Lee, K.H. (Ki Hyeong)\|\|\|/items/494d4428-b76a-475d-a658-c74ee1ade123, Migliorino, M.R. (Maria Rita)\|\|\|/items/9abafe36-e406-4036-b7f4-de06f44c197f, Pluzanski, A. (Adam)\|\|\|/items/60793365-1e98-4ea9-8e43-b3df9623206c, Linke, R. (Rolf)\|\|\|/items/07873284-7c5d-4745-b966-cff39ed3b29d, Devgan, G. (Geeta)\|\|\|/items/fb3e0082-1314-470f-91f3-6e2b9787a62d, Tan, W. (Weiwei)\|\|\|/items/55ef5622-8ca9-4887-a576-36b6711f47dc, Quinn, S. (Susan)\|\|\|/items/1e0851a9-c13a-4765-97f3-d086cb24a7cc, Wang, T. (Tao)\|\|\|/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3, Wu, Y.L. (Yi-Long)\|\|\|/items/7a103463-4dcc-4ad4-87d3-0c0081a787df
Tipo de recurso:	artículo
Fecha de publicación:	2019
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/62028
Acceso en línea:	https://hdl.handle.net/10171/62028
Access Level:	acceso abierto
Palabra clave:	Materias Investigacion::Ciencias de la Salud::Oncología EGFR NSCLC Dacomitinib Dose First-line

id	ES_7f8a8008e993cbda35aad67b7a2669a2
oai_identifier_str	oai:dadun.unav.edu:10171/62028
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancerCorral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852Mok, T.S. (Tony S.)\|\|\|/items/e91edeb3-d511-44a4-a72c-338e96ade778Nakagawa, K. (Kazuhiko)\|\|\|/items/04e7db33-fd42-4c2b-a989-0d6a89ae878aRosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0Lee, K.H. (Ki Hyeong)\|\|\|/items/494d4428-b76a-475d-a658-c74ee1ade123Migliorino, M.R. (Maria Rita)\|\|\|/items/9abafe36-e406-4036-b7f4-de06f44c197fPluzanski, A. (Adam)\|\|\|/items/60793365-1e98-4ea9-8e43-b3df9623206cLinke, R. (Rolf)\|\|\|/items/07873284-7c5d-4745-b966-cff39ed3b29dDevgan, G. (Geeta)\|\|\|/items/fb3e0082-1314-470f-91f3-6e2b9787a62dTan, W. (Weiwei)\|\|\|/items/55ef5622-8ca9-4887-a576-36b6711f47dcQuinn, S. (Susan)\|\|\|/items/1e0851a9-c13a-4765-97f3-d086cb24a7ccWang, T. (Tao)\|\|\|/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3Wu, Y.L. (Yi-Long)\|\|\|/items/7a103463-4dcc-4ad4-87d3-0c0081a787dfMaterias Investigacion::Ciencias de la Salud::OncologíaEGFRNSCLCDacomitinibDoseFirst-lineAim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement.Future Medicine LtdDadun. Depósito Académico Digital Universidad de Navarra20212021-09-2020192019-01-0120192019-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/62028reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/620282026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
title	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
spellingShingle	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer Corral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852 Materias Investigacion::Ciencias de la Salud::Oncología EGFR NSCLC Dacomitinib Dose First-line
title_short	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
title_full	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
title_fullStr	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
title_full_unstemmed	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
title_sort	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer
dc.creator.none.fl_str_mv	Corral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852 Mok, T.S. (Tony S.)\|\|\|/items/e91edeb3-d511-44a4-a72c-338e96ade778 Nakagawa, K. (Kazuhiko)\|\|\|/items/04e7db33-fd42-4c2b-a989-0d6a89ae878a Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0 Lee, K.H. (Ki Hyeong)\|\|\|/items/494d4428-b76a-475d-a658-c74ee1ade123 Migliorino, M.R. (Maria Rita)\|\|\|/items/9abafe36-e406-4036-b7f4-de06f44c197f Pluzanski, A. (Adam)\|\|\|/items/60793365-1e98-4ea9-8e43-b3df9623206c Linke, R. (Rolf)\|\|\|/items/07873284-7c5d-4745-b966-cff39ed3b29d Devgan, G. (Geeta)\|\|\|/items/fb3e0082-1314-470f-91f3-6e2b9787a62d Tan, W. (Weiwei)\|\|\|/items/55ef5622-8ca9-4887-a576-36b6711f47dc Quinn, S. (Susan)\|\|\|/items/1e0851a9-c13a-4765-97f3-d086cb24a7cc Wang, T. (Tao)\|\|\|/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3 Wu, Y.L. (Yi-Long)\|\|\|/items/7a103463-4dcc-4ad4-87d3-0c0081a787df
author	Corral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852
author_facet	Corral-Jaime, J. (Jesús)\|\|\|/items/aba4503e-6970-43e0-9219-238766ac8852 Mok, T.S. (Tony S.)\|\|\|/items/e91edeb3-d511-44a4-a72c-338e96ade778 Nakagawa, K. (Kazuhiko)\|\|\|/items/04e7db33-fd42-4c2b-a989-0d6a89ae878a Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0 Lee, K.H. (Ki Hyeong)\|\|\|/items/494d4428-b76a-475d-a658-c74ee1ade123 Migliorino, M.R. (Maria Rita)\|\|\|/items/9abafe36-e406-4036-b7f4-de06f44c197f Pluzanski, A. (Adam)\|\|\|/items/60793365-1e98-4ea9-8e43-b3df9623206c Linke, R. (Rolf)\|\|\|/items/07873284-7c5d-4745-b966-cff39ed3b29d Devgan, G. (Geeta)\|\|\|/items/fb3e0082-1314-470f-91f3-6e2b9787a62d Tan, W. (Weiwei)\|\|\|/items/55ef5622-8ca9-4887-a576-36b6711f47dc Quinn, S. (Susan)\|\|\|/items/1e0851a9-c13a-4765-97f3-d086cb24a7cc Wang, T. (Tao)\|\|\|/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3 Wu, Y.L. (Yi-Long)\|\|\|/items/7a103463-4dcc-4ad4-87d3-0c0081a787df
author_role	author
author2	Mok, T.S. (Tony S.)\|\|\|/items/e91edeb3-d511-44a4-a72c-338e96ade778 Nakagawa, K. (Kazuhiko)\|\|\|/items/04e7db33-fd42-4c2b-a989-0d6a89ae878a Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0 Lee, K.H. (Ki Hyeong)\|\|\|/items/494d4428-b76a-475d-a658-c74ee1ade123 Migliorino, M.R. (Maria Rita)\|\|\|/items/9abafe36-e406-4036-b7f4-de06f44c197f Pluzanski, A. (Adam)\|\|\|/items/60793365-1e98-4ea9-8e43-b3df9623206c Linke, R. (Rolf)\|\|\|/items/07873284-7c5d-4745-b966-cff39ed3b29d Devgan, G. (Geeta)\|\|\|/items/fb3e0082-1314-470f-91f3-6e2b9787a62d Tan, W. (Weiwei)\|\|\|/items/55ef5622-8ca9-4887-a576-36b6711f47dc Quinn, S. (Susan)\|\|\|/items/1e0851a9-c13a-4765-97f3-d086cb24a7cc Wang, T. (Tao)\|\|\|/items/6e6bf742-59a8-45e8-a19a-07e87e41dea3 Wu, Y.L. (Yi-Long)\|\|\|/items/7a103463-4dcc-4ad4-87d3-0c0081a787df
author2_role	author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Materias Investigacion::Ciencias de la Salud::Oncología EGFR NSCLC Dacomitinib Dose First-line
topic	Materias Investigacion::Ciencias de la Salud::Oncología EGFR NSCLC Dacomitinib Dose First-line
description	Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement.
publishDate	2019
dc.date.none.fl_str_mv	2019 2019-01-01 2019 2019-01-01 2021 2021-09-20
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/62028
url	https://hdl.handle.net/10171/62028
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Future Medicine Ltd
publisher.none.fl_str_mv	Future Medicine Ltd
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869411832198856704
score	15,300719

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Similares en LA Referencia